LARONI , A

Last name: LARONI

First name: A

2019 (v1)

Publication

Metadata-only

Ageing with MS: a cross sectional study

Michelis, D Brunetti, N Solaro, C

No description

Uploaded on: March 3, 2024
2022 (v1)

Publication

Metadata-only

Mesenchymal stem cells for multiple sclerosis: effect of treatment on peripheral immune cells

Schiavetti, I Freedman, MS Martino, G

No description

Uploaded on: February 25, 2024
2023 (v1)

Publication

Metadata-only

Hypothalamic AgRP neurons control hematopoiesis and lymphopoiesis and are activated in experimental MS

Vigo, T Mariani, MC Ferrara, G

No description

Uploaded on: February 25, 2024
2023 (v1)

Publication

Metadata-only

The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis

Sirito, T Boffa, G Lapucci, C

No description

Uploaded on: February 25, 2024
2022 (v1)

Publication

Metadata-only

Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study

Cellerino, M Mancuso, E Boffa, G

No description

Uploaded on: March 3, 2024
2023 (v1)

Publication

Metadata-only

The effect of Cladribine and Fingolimod treatments on retinal atrophy

Cellerino, M Sirito, T Maneschi, V

No description

Uploaded on: February 25, 2024
2023 (v1)

Publication

Metadata-only

The short-chain fatty acid butyrate decreases the regulatory function of human natural killer cells and promotes their maturation

Carlini, F Squillario, M Capaia, M

No description

Uploaded on: February 25, 2024
2022 (v1)

Publication

Metadata-only

Vaccinations in patients with multiple sclerosis: a real-world, single-center, experience

Sbragia, E Olobardi, D Novi, G

No description

Uploaded on: March 3, 2024
2022 (v1)

Publication

Metadata-only

Beyond steady-state amyloid PET to detect demyelination in multiple sclerosis (MS)

Donegani, M Pardini, M Chincarini, A

No description

Uploaded on: February 27, 2024
2020 (v1)

Publication

Metadata-only

Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab

Boffa, G Lapucci, C Sbragia, E

Background and purpose The best therapeutic approach for aggressive relapsing-remitting multiple sclerosis remains unknown. The objective was to compare the efficacy and safety of autologous haematopoietic stem cell transplantation (aHSCT) and alemtuzumab in aggressive relapsing-remitting multiple sclerosis. Methods The time to first relapse,...

Uploaded on: April 14, 2023

LARONI , A

Recent uploads